Sentences with phrase «developed as a cancer therapy»

Not exact matches

Synthetic marijuana was first developed in the South Carolina lab of a Clemson University professor as part of research into therapies for osteoporosis, liver disease and some kinds of cancer.

Drugs that target VCP are already being developed as potential therapies for cancer.

The type, intensity and duration of immunosuppressive therapy contribute to the risk of developing skin cancer, such as melanoma, after transplantation.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

«It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune - mediated diseases as well as other epigenetically - influenced diseases,» said Alani, who also is chief of dermatology at Boston Medical Center.

«As these drugs are considerably cheaper than current therapies, they can improve treatment in the developing world where the number of deaths from cancer is predicted to increase significantly over the next ten years,» said Dr Federica Sotgia, another leader of the study.

«This is why we're diligently working to employ several strategies that we hope will lead us to reaching our ultimate goal of developing the best therapy possible — a therapy that can be given to patients as a first line of defense, greatly reducing the side effects of cancer treatment and leading to a cure.»

In cases of new infection, prompt and targeted therapy is vital, as it can prevent the disease developing into a chronic condition that can lead to inoperable liver cancer.

Epigenetic therapies are rapidly being developed as cancer treatments, opening the possibility to also test these drugs for antiviral activity.

The process, which located a genetic site for the most common form of prostate cancer, has potential for developing precision therapy for other cancers, such as breast, brain and colorectal, say researchers at The University of Texas MD Anderson Cancer Ccancer, has potential for developing precision therapy for other cancers, such as breast, brain and colorectal, say researchers at The University of Texas MD Anderson Cancer CCancer Center.

Dr. Cooper joined MDACC in 2006 as section chief of cell therapy at the Children's Cancer Hospital, where he cared for children undergoing bone marrow transplantation and led scientific efforts to develop new treatment approaches that pair genetic engineering with immunotherapies.

Schiffman plans to use what he's learned in elephants as a strategy for developing novel cancer - fighting therapies.

And while new therapies have been effective in releasing the immune system's restraints to unleash the body's own cancer - fighting powers, they only work in about half of melanoma patients and often lose their potency as the cancer develops resistance.

Because diseases such as cancer tend to evade detection by T - cells» receptors, allowing a tumor to grow unchecked, scientists have long sought «intel» on this process as a means of developing therapies that target malignant cells, but leave healthy cells alone.

«Our hope is that by understanding this relationship, we may be able to predict which people are most likely to develop certain cancers so they can take preventive measures and perhaps be screened more often, as well as develop therapies to help our DNA keep or return its telomeres to a healthy length.»

A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

«Current therapies take advantage of this by using targeted drugs such as Trastuzumab or Lapatinib to specifically inhibit ERBB2, but eventually they become ineffective as the cancer develops resistance to those drugs.»

Most lung cancer patients undergo 4D CT as standard - of - care to help radiation oncologists develop a personalized plan to account for breathing motion during therapy.

In 2012, the St. Jude Children's Research Hospital — Washington University Pediatric Cancer Genome Project highlighted DDX3X as a promising focus for efforts to develop targeted therapies against medulloblastoma.

People with breast cancer or lymphoma were three times as likely to develop heart failure within five years of their cancer diagnosis, and 20 years following cancer treatment were still nearly twice as likely to have been diagnosed with heart failure compared to similar patients who didn't undergo cancer therapy.

In my role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, I am developing novel therapies for patients with cCancer Center, I am developing novel therapies for patients with cancercancer.

The company is developing CAR T - cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases.

This year's Action Award honorees include global leaders in the fight to end cancer as we know it; a world leader in advancing the emerging field of regenerative medicine and game - changing cell therapy medical treatments; the president of a non-profit group focused on developing cures for chronic, debilitating and fatal diseases; a sickle cell and stem cell advocate and founder / science administrator of the Axis Advocacy; and the founding director of the Institute for Integrated Cell - Material Sciences (iCeMS) at Japan's Kyoto University.

«Developing therapies for each subtype independent of the other may improve outcomes, as has been shown in breast cancer.»

The findings, published in Cell, may help scientists develop new therapies for neurological disorders, such as amyotrophic lateral sclerosis (ALS), and provide insight into certain cancers.

We look forward to reporting on our progress as we work to develop therapies that we believe could benefit patients with a wide - range of cancers.»

The long - term vision is to apply these technologies to other genetic diseases, such as sickle cell disease, and to explore applications in developing effective immune therapies for cancer.

Because of their unique properties such as monodispersity, large surface area and high drug loading efficiency, silica nanoparticles (SiNPs) have been developed for a vast array of biomedical uses such as optical imaging, cancer therapy, targeted drug delivery and controlled drug release for genes and proteins.

A bioengineer in the College of Engineering and Computer Science at Florida Atlantic University has received a $ 141,743 grant from the National Cancer Institute of the National Institutes of Health to develop a novel biodegradable polymer stent that will be designed to prevent complications while at the same time serving as a drug delivery system for esophageal cancer thCancer Institute of the National Institutes of Health to develop a novel biodegradable polymer stent that will be designed to prevent complications while at the same time serving as a drug delivery system for esophageal cancer thcancer therapy.

This enzyme, formally acetyl - CoA carboxylase, is of interest to researchers developing therapies for metabolic diseases such as obesity and diabetes and for certain cancers in which ACC is upregulated.

By studying them, we are beginning to gain insight into human disease — to understand why organs such as the heart can not repair themselves or why, as we age, the incidence of debilitating diseases such as cancer, heart disease and Alzheimer's increases so rapidly, and we are developing new therapies that will enhance our abilities to regenerate damaged tissues and prolong healthy lifespan.

More than a dozen experimental clinical therapies and vaccines have been developed from research from the Weiner laboratory, including the first Zika vaccine in clinical trials, as well as a novel immunotherapy for HPV - associated cancer and precancer.

«We are committing everything we have, every resource at our disposal, to developing the therapies that will improve the lives of the millions of people worldwide who live with the hepatitis B virus every day, as well as the risk of dying prematurely from its most fatal consequence, liver cancer.»

By learning as much as possible about those unique changes, and developing specific drugs and therapies to target them, we at City of Hope believe many cancers can be defeated at the molecular level, often with fewer side effects compared to traditional chemotherapy and other treatments.

As the Director of the Early Phase Clinical Trials Program at Roswell Park, I am responsible for developing novel therapies for many types of cancer, including melanoma.

PHILADELPHIA — A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

Cancers in dogs, such as bone cancer, lymphoma and many other types of tumors, are almost identical to those same kinds found in humans and they tend to develop faster and run their course quicker, so it's an ideal way to see if a certain therapy will work.

1) Equitable drug design: The BRF is committed to developing new therapies, especially designed to treat cancer in pets but also to benefit people as well.

Most notably, Sean led the firm's representation of over 1,200 Enron employees and shareholders for losses they sustained as a result of the company's collapse, and was lead counsel for the firm's work on behalf of women who developed breast cancer as a result of hormone replacement therapy.

Developed in response to these considerations, the protocol of this current intervention — Caregiver of cancer Outpatients PsychoEducation support group therapy, or known as COPE — is described here.

Although daily low - dose aspirin isn't for everyone, new research suggests that middle - aged people on aspirin therapy may have as much as a 25 percent lower risk of developing colon cancer.